Komori
Intertrade (3747) · InitiativeSoftened

Strengthening the financial position and stabilising liquidity through financing

First written in FY2019. 6 of 14 entries say "Restated". Latest entry: FY2025.

14entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY2021-Q3OtherFY2024-Q2 – FY2025-H12019: 12020: 220202021: 320212022: 120222023: 320232024: 220242025: 22025
Same theme, other companies

2 other companies' latest entry also says "Softened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 108 companies compared. The sentences above are computed from all 108.
Full recordFilings, disclosures and news, newest first
  1. FY2025Reorganisation around a financing policy based primarily on internal fundsAnnual report

    「Our basic policy is to secure the funds required for business activities on a stable basis. Our financing policy is based primarily on internal funds.」

    The company's financing policy was reorganised from its previous emphasis on expanding borrowings from financial institutions to a policy based primarily on internal funds, with consideration given to various financing methods as necessary. During the fiscal year, the company repaid ¥40 million in long-term borrowings, and financing activities resulted in a cash outflow of ¥47 million.
  2. FY2025-H1Financing cash outflow from repayment of long-term borrowingsAnnual report

    「Net cash used in financing activities was ¥24 million, compared with net cash used of ¥13 million in the same period of the previous year. The main factors behind the decrease were ¥20 million in repayments of long-term borrowings and ¥4 million in repayments of lease liabilities, among other items.」

    Net cash used in financing activities was ¥24 million, and repayments including ¥20 million of long-term borrowings were disclosed. This indicates a repayment phase rather than financing through new borrowings.
  3. FY2024RestatedAnnual report

    「Net cash provided by financing activities was ¥73 million, compared with ¥70 million in the same period of the previous year. The main factor behind the increase was ¥100 million in proceeds from long-term borrowings, among other items.」

    The company continued to record ¥100 million in proceeds from long-term borrowings, continuing to secure its financial base and liquidity through financing.
  4. FY2024-Q2Financing cash outflows from debt repaymentsAnnual report

    「Net cash used in financing activities was ¥13 million, compared with net cash provided of ¥88 million in the same period of the previous year. The main factors behind the decrease were ¥10 million in repayments of long-term borrowings and ¥3 million in repayments of lease liabilities, among other items.」

    Net cash from financing activities changed from net cash provided of ¥88 million in the same period of the previous year to net cash used of ¥13 million, and the company disclosed repayments including ¥10 million of long-term borrowings.
  5. FY2023AdvancedAnnual report

    「Net cash provided by financing activities was ¥70 million, compared with net cash used of ¥10 million in the previous consolidated fiscal year. The main factor behind the increase was ¥100 million in proceeds from long-term borrowings, among other items.」

    Due to ¥100 million in proceeds from long-term borrowings, net cash provided by financing activities changed from net cash used of ¥10 million in the previous year to net cash provided of ¥70 million.
  6. FY2023-Q3RestatedAnnual report

    「Total overdraft facility limit ¥400 million Drawn balance ¥100 million Undrawn amount ¥300 million」

    For the overdraft facility with 1 of the company's banks, the company continues to disclose a facility limit of ¥400 million, a drawn balance of ¥100 million, and an undrawn amount of ¥300 million.
  7. FY2023-Q2AdvancedAnnual report

    「Net cash provided by financing activities was ¥88 million, compared with net cash used of ¥5 million in the same period of the previous year. The main factor behind the increase was ¥100 million in proceeds from long-term borrowings, among other items.」

    The company received ¥100 million from long-term borrowings, and net cash provided by financing activities changed from net cash used of ¥5 million in the same period of the previous year to net cash provided of ¥88 million. The company disclosed concrete progress in financing.
  8. FY2022-Q3RestatedAnnual report

    「Total overdraft facility limit ¥400 million Drawn balance ¥100 million Undrawn amount ¥300 million」

    For the overdraft facility with 1 of the company's banks, the company continues to disclose a facility limit of ¥400 million, a drawn balance of ¥100 million, and an undrawn amount of ¥300 million.
  9. FY2021AdvancedAnnual report

    「Total overdraft facility limit ¥400 million Drawn balance ¥100 million Undrawn amount ¥300 million」

    The overdraft facility limit remained at ¥400 million, while the drawn balance decreased from ¥200 million to ¥100 million and the undrawn amount increased from ¥200 million to ¥300 million.
  10. FY2021-Q3RestatedAnnual report

    「Total overdraft facility limit ¥400 million Drawn balance ¥200 million Undrawn amount ¥200 million」

    For the overdraft facility with 1 of the company's banks, the company continues to disclose a facility limit of ¥400 million, a drawn balance of ¥200 million, and an undrawn amount of ¥200 million.
  11. FY2021-Q2RestatedAnnual report

    「Total overdraft facility limit ¥400 million Drawn balance ¥200 million Undrawn amount ¥200 million」

    For the overdraft facility with 1 of the company's banks, the company continues to disclose a facility limit of ¥400 million, a drawn balance of ¥200 million, and an undrawn amount of ¥200 million.
  12. FY2020RestatedAnnual report

    「Our group is working to strengthen its financial position in order to maintain sound management, but funds will be needed to strengthen and expand the business going forward. In addition to cash on hand, we will raise funds and build a financial foundation capable of withstanding risks.」

    The company continues to pursue a policy of stabilising its financial base and liquidity through financing in addition to cash on hand, borrowings from financial institutions and overdraft facilities.
  13. FY2020-Q2AdvancedAnnual report

    「Net cash provided by financing activities was ¥162 million, compared with net cash used of ¥24 million in the same period of the previous year. The main factors were a ¥100 million net decrease in short-term borrowings and ¥281 million in proceeds from payments by non-controlling interests.」

    The company received ¥281 million from payments by non-controlling interests, disclosing concrete progress in strengthening its financial base and stabilising liquidity through financing.
  14. FY2019First statedAnnual report

    「Our group is working to strengthen its financial position in order to maintain sound management, but funds will be needed to strengthen and expand the business going forward. In addition to cash on hand, we will raise funds and build a financial foundation capable of withstanding risks. We currently meet our financing needs through borrowings from financial institutions with which we do business, including overdraft facilities, and will seek to further enhance these arrangements by expanding the scale of existing transactions and establishing new relationships, thereby working to stabilise liquidity.」

    The company identified strengthening its financial position as an issue and, for the first time, extracted it as an independent theme, outlining a policy of stabilising liquidity through financing in addition to cash on hand, borrowings including overdraft facilities, and expanded and new transactions with financial institutions.
Moved together

"Healthcare business remains loss-making" moved the same way as this thread, in the same document, in 4 of its 14 moves.

433222★123456
  1. ★This thread
  2. 1Healthcare business remains loss-making4×
  3. 2Concentration on the IT Hanabiratake business following the sale of the healthcare mail-order business3×
  4. 3Building a revenue base through expanded sales of GroupMAN@IT e²3×
  5. 4Expanding sales of Hanabiratake products, centered on the βeauty Glucan brand2×
  6. 5Stable growth and transition to a renewed growth phase through a better-balanced business portfolio2×
  7. 6Business solutions business: dependence on spot projects, declining revenue and losses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Intertrade's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.